Trials / Completed
CompletedNCT00988260
Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)
A Phase II Bridging Trial of Org 37462
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 266 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- Female
- Age
- 20 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the optimal dose of Org 37462 for Japanese females undergoing controlled ovarian stimulation for in vitro fertilization intracytoplasmic sperm injection (IVF-ICSI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganirelix | Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days |
| DRUG | Ganirelix | Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days |
| DRUG | Ganirelix | Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days |
Timeline
- Start date
- 2003-02-03
- Primary completion
- 2004-04-12
- Completion
- 2004-04-12
- First posted
- 2009-10-02
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00988260. Inclusion in this directory is not an endorsement.